| Primary |
| Growth Hormone Deficiency |
17.7% |
| Hypopituitarism |
11.6% |
| Primary Hypothyroidism |
6.9% |
| Blood Corticotrophin Decreased |
5.5% |
| Blood Thyroid Stimulating Hormone Decreased |
5.3% |
| Blood Follicle Stimulating Hormone Decreased |
5.1% |
| Blood Luteinising Hormone Decreased |
5.1% |
| Follicle-stimulating Hormone Deficiency |
4.9% |
| Acth Decreased |
4.8% |
| Hypertension |
4.4% |
| Essential Hypertension |
3.7% |
| Body Height Below Normal |
3.5% |
| Hypothyroidism |
3.4% |
| Luteinising Hormone Deficiency |
3.3% |
| Hypogonadism |
2.8% |
| Hypogonadism Female |
2.6% |
| Tsh Decreased |
2.5% |
| Asthma |
2.5% |
| Thyroid Disorder |
2.4% |
| Hypogonadism Male |
2.0% |
|
| Death |
11.0% |
| Headache |
9.8% |
| Neoplasm Recurrence |
7.9% |
| Injection Site Pain |
7.6% |
| Vomiting |
7.4% |
| Pituitary Tumour Benign |
6.6% |
| Arthropathy |
6.4% |
| Pneumonia |
5.7% |
| Weight Increased |
4.2% |
| Pyrexia |
4.1% |
| Drug Ineffective |
3.9% |
| Rash |
3.7% |
| Oedema Peripheral |
3.2% |
| Sleep Apnoea Syndrome |
3.0% |
| Pain In Extremity |
2.9% |
| Epilepsy |
2.8% |
| Cardiac Disorder |
2.4% |
| Convulsion |
2.4% |
| Injection Site Haemorrhage |
2.4% |
| Hypertension |
2.2% |
|
| Secondary |
| Growth Hormone Deficiency |
22.9% |
| Hypopituitarism |
16.9% |
| Body Height Below Normal |
11.3% |
| Asthma |
7.4% |
| Hypertension |
4.7% |
| Dwarfism |
4.5% |
| Growth Retardation |
4.4% |
| Hypothyroidism |
4.0% |
| Thyroid Disorder |
2.7% |
| Blood Corticotrophin Decreased |
2.6% |
| Turner's Syndrome |
2.5% |
| Prader-willi Syndrome |
2.4% |
| Off Label Use |
2.2% |
| Attention Deficit/hyperactivity Disorder |
2.1% |
| Small For Dates Baby |
2.0% |
| Renal Failure Chronic |
1.7% |
| Depression |
1.5% |
| Scleroderma |
1.5% |
| Blood Growth Hormone Decreased |
1.4% |
| Hypersensitivity |
1.2% |
|
| Headache |
17.1% |
| Platelet Count Decreased |
6.9% |
| Weight Increased |
6.5% |
| Vomiting |
6.1% |
| Injection Site Pain |
5.3% |
| Neoplasm Recurrence |
4.9% |
| Off Label Use |
4.5% |
| Circumstance Or Information Capable Of Leading To Medication Error |
4.1% |
| Convulsion |
4.1% |
| Pain In Extremity |
4.1% |
| Pneumonia |
4.1% |
| Sleep Apnoea Syndrome |
4.1% |
| Brain Neoplasm |
3.7% |
| Fatigue |
3.7% |
| Hypertension |
3.7% |
| Osteogenesis Imperfecta |
3.7% |
| Pituitary Tumour Benign |
3.7% |
| Scoliosis |
3.7% |
| Meniscus Lesion |
3.3% |
| Neoplasm |
3.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.8% |
| Ill-defined Disorder |
8.0% |
| Drug Use For Unknown Indication |
6.5% |
| Crohn's Disease |
5.5% |
| Empty Sella Syndrome |
5.5% |
| Malabsorption |
4.9% |
| Gastrooesophageal Reflux Disease |
4.0% |
| Growth Hormone Deficiency |
3.7% |
| Prophylaxis |
3.7% |
| Hypothyroidism |
3.4% |
| Cystinosis |
3.1% |
| Hypopituitarism |
3.1% |
| Type 2 Diabetes Mellitus |
3.1% |
| Hypertension |
2.8% |
| Blood Cholesterol Increased |
2.5% |
| Dermatitis Atopic |
2.2% |
| Hypersensitivity |
2.2% |
| Juvenile Arthritis |
2.2% |
| Neuropathy Peripheral |
2.2% |
| Anaemia |
1.8% |
|
| Pulmonary Fibrosis |
14.3% |
| Weight Increased |
12.7% |
| Glycosylated Haemoglobin Increased |
6.3% |
| Vomiting |
6.3% |
| Wound Infection Bacterial |
6.3% |
| Blood Creatinine Increased |
4.8% |
| Colorectal Cancer |
4.8% |
| Neutropenia |
4.8% |
| Treatment Noncompliance |
4.8% |
| Vision Blurred |
4.8% |
| Goitre |
3.2% |
| Hypomania |
3.2% |
| Limb Injury |
3.2% |
| Nausea |
3.2% |
| Pancreatic Carcinoma |
3.2% |
| Pharmaceutical Product Complaint |
3.2% |
| Rash Erythematous |
3.2% |
| Vitreous Detachment |
3.2% |
| Weight Decreased |
3.2% |
| Abdominal Distension |
1.6% |
|
| Interacting |
| Hypopituitarism |
27.3% |
| Thyroid Disorder |
18.2% |
| Adrenal Insufficiency |
9.1% |
| Cerebral Thrombosis |
9.1% |
| Cerebrovascular Accident |
9.1% |
| Growth Hormone Deficiency |
9.1% |
| Hypothyroidism |
9.1% |
| Thrombosis |
9.1% |
|
| Drug Interaction |
66.7% |
| International Normalised Ratio Abnormal |
33.3% |
|
